SYNTHESIS OF A N'-ALKYLAMINE ANTICOAGULANT ACTIVE LOW-MOLECULAR-MASS HEPARIN FOR RADIOACTIVE AND FLUORESCENT LABELING

被引:38
作者
MALSCH, R [1 ]
GUERRINI, M [1 ]
TORRI, G [1 ]
LOHR, G [1 ]
CASU, B [1 ]
HARENBERG, J [1 ]
机构
[1] INST CHIM & BIOCHIM G RONZONI, I-20133 MILAN, ITALY
关键词
D O I
10.1006/abio.1994.1117
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Heparin plays an important role in anticoagulation and several other biological processes. Cleavage of heparin by nitrous acid results in a reactive 2,5-anhydromannose (Am) which can be used to selectively insert primary and secondary amines by reductive amination. Low-molecular-mass heparin (LMMH) was bound to 4-(2-aminoethylphenol) as shown by nuclear magnetic resonance spectroscopy (NMR), high-performance size-exclusion chromatography (HPSEC), polyacrylamide gel electrophoresis (PAGE), and ultraviolet/visible (uv/vis) spectroscopy. H-1 NMR spectra revealed an average sequence of (IdoA2SO(3)-GlcNSO3 6SO(3))(9)-IdoAaSO(3)-Am-tyramine and a 50% binding rate of tyramine to LMMH. LMMH-Tyr had an anticoagulant activity of 108 antifactor Xa activity (aXa) U/mg and 42 antifactor IIa activity (aIIa) U/mg. The compound was neutralized by protamine. The N-alkylamine derivative was adopted to label LMMH with iodine-125 by oxidation with chloramine T. Fluorescein-5-isothiocyanate (Fitc) was used to label LMMH-Tyr with fluorescence. NMR, HPSEC, PAGE, and uv/vis spectroscopy demonstrated the binding of Fitc to LMMH-Tyr. H-1 NMR spectra indicated that about 80% of the LMMH-Tyr was labeled at the secondary amino group. The fluorescent compound exhibited 70 aXa and 5 aIIa U/mg and was neutralized by protamine. The selectively bound labeled heparin derivatives are ''endpoint attached'' and have intact anticoagulant activity. (C) 1994 Academic Press, Inc.
引用
收藏
页码:255 / 264
页数:10
相关论文
共 30 条
[1]  
ALBAN S, 1991, PHARM PHARM LETT, V1, P37
[2]  
BARA L, 1987, HAEMOSTASIS, V17, P127
[3]   STRUCTURE AND BIOLOGICAL-ACTIVITY OF HEPARIN [J].
CASU, B .
ADVANCES IN CARBOHYDRATE CHEMISTRY AND BIOCHEMISTRY, 1985, 43 :51-134
[4]  
CASU B, 1989, ANN NY ACAD SCI, V556, P1
[5]  
DAWES J, 1991, THROMB HAEMOSTASIS, V65, P829
[6]   COMPARATIVE EFFICACY OF A NEW CLOT-BASED ANTI-XA IIA ASSAY AND AN AMIDOLYTIC ANTI-XA METHOD DURING A VERY LOW-MOLECULAR-WEIGHT HEPARIN FRAGMENT (CY-222) TREATMENT [J].
DELAHOUSSE, B ;
GRUEL, Y ;
MOALIC, P ;
TOULEMONDE, F ;
LEROY, J .
THROMBOSIS RESEARCH, 1987, 46 (02) :405-407
[7]   GRADIENT POLYACRYLAMIDE-GEL ELECTROPHORESIS FOR DETERMINATION OF MOLECULAR-WEIGHTS OF HEPARIN PREPARATIONS AND LOW-MOLECULAR-WEIGHT HEPARIN DERIVATIVES [J].
EDENS, RE ;
ALHAKIM, A ;
WEILER, JM ;
RETHWISCH, DG ;
FAREED, J ;
LINHARDT, RJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1992, 81 (08) :823-827
[8]   ANGIOGENESIS INHIBITION AND TUMOR-REGRESSION CAUSED BY HEPARIN OR A HEPARIN FRAGMENT IN THE PRESENCE OF CORTISONE [J].
FOLKMAN, J ;
LANGER, R ;
LINHARDT, RJ ;
HAUDENSCHILD, C ;
TAYLOR, S .
SCIENCE, 1983, 221 (4612) :719-725
[9]   PREPARATION OF 131I-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY [J].
GREENWOOD, FC ;
HUNTER, WM .
BIOCHEMICAL JOURNAL, 1963, 89 (01) :114-&
[10]   CHARACTERIZATION OF HEPARINS BY HIGH-PERFORMANCE SIZE EXCLUSION LIQUID-CHROMATOGRAPHY [J].
HARENBERG, J ;
DEVRIES, JX .
JOURNAL OF CHROMATOGRAPHY, 1983, 261 (02) :287-292